December 17, 2020: We need at least 1 year of blinded, randomized, controlled data. We agree that FDA should delay access to vaccines by members of the placebo group unless they are in priority populations.
Read More »On Medical Treatments & Products
NCHR’s Comments Regarding Spironolactone for Heart Failure with Preserved Ejection Fraction
December 16, 2020: What can be done to improve the quality of the data prior to FDA making a decision about whether or not to approve a new indication for spironolactone?
Read More »Testimony of Dr. Diana Zuckerman of NCHR before the FDA Advisory Committee on Pfizer COVID Vaccine
December 10, 2020: We need longer-term data on the Pfizer COVID-19 vaccine to fully understand if benefits outweigh the risks for frail patients and all races/ethnicities, and for everyone else as well. It is essential that FDA ensure the continuation of the randomized controlled trial.
Read More »Public Comments Regarding ACIP Meeting on December 1, 2020
December 1, 2020: We are concerned about the lack of data on the vaccines in patients living in long-term care facilities, or any patients over 65 years of age.
Read More »NCHR’s Comments on Drug Labeling for Geriatric Patients
November 16, 2020: We agree that the FDA should immediately develop clear guidelines for labeling that addresses safety and effectiveness of drugs in the geriatric population.
Read More »